Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "PLI"

3328 News Found

Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares
Clinical Trials | September 16, 2025

Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares

ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases


Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
News | September 16, 2025

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke


CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR
Healthcare | September 16, 2025

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness


Syensqo introduces medical-grade Amodel PPA for medical devicess
Medical Device | September 16, 2025

Syensqo introduces medical-grade Amodel PPA for medical devicess

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies


Drug Hunter secures seed investment to scale drug discovery knowledge platform
R&D | September 16, 2025

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management


Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
Clinical Trials | September 16, 2025

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program


Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Clinical Trials | September 16, 2025

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


Goa to host historic 10th Ayurveda day on September 23
News | September 16, 2025

Goa to host historic 10th Ayurveda day on September 23

We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav


Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC
Clinical Trials | September 16, 2025

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone